What's happening?

At Recipharm, we are dedicated to supporting our customers when they need it most, particularly in these testing times since the outbreak of COVID-19. We are aware that our customers need to work quickly and efficiently, and the current travel restrictions that are in place create many challenges.

Unmet patient needs and ongoing advances in science and technology are the growth engines behind inhalation therapy.

Given the prevalence of the COVID-19 virus, Recipharm has been experiencing an increase in demand for antibiotic production. With the current climate, the supply of antibiotics is especially important as secondary bacterial infections are very common in severely ill COVID-19 patients.

Third party providers offer both the infrastructure and breadth of experience to help clients arrange testing programmes that are relevant, cost-effective and as streamlined as possible.

Multiple API products can offer improved efficacy while avoiding the need for patients to administer several drugs from different devices.

The UK’s official exit from the EU on January 31st marked the start of a year-long transition period, with a temporary deal agreed with the EU to keep the terms of trade relatively stable, at least for now.

In recent years, there have been many changes within the pharmaceutical industry that have influenced a surge in demand for CDMOs.

A CDMO with inhalation development experience will understand the intricacies involved with and the unique requirements of the development pathway.

With a central focus on human safety, high quality standards for drug products are upheld worldwide through various drug agencies.

Understanding regional differences, implementing best-practice documentation processes key to successful approval outcomes